Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 12/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.39 |
| ▸ | PLK4 | O00444 | 4/20 | 0.39 |
| ▸ | GSK3B | P49841 | 4/20 | 0.39 |
| ▸ | PAK4 | O96013 | 4/20 | 0.39 |
| ▸ | SRC | P12931 | 3/20 | 0.39 |
| ▸ | ABL1 | P00519 | 3/20 | 0.39 |
| ▸ | LCK | P06239 | 3/20 | 0.39 |
| ▸ | CSF1R | P07333 | 3/20 | 0.39 |
| ▸ | RET | P07949 | 3/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | FLT3 | P36888 | 3/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.39 |
| ▸ | KIT | P10721 | 2/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.39 |
| ▸ | TYK2 | P29597 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10312219 | 0.89 | AURKA (0.41) | AURKAAURKBPLK4GSK3BPAK4 | |
| SCHEMBL10312162 | 0.87 | IGF1R (0.45) | SRCIGF1R | |
| SCHEMBL10312077 | 0.87 | DHODH (0.46) | AURKAAURKBPLK4GSK3BPAK4 | |
| SCHEMBL10312136 | 0.81 | PTGS2 (0.35) | AURKANPC1RAB9AAURKBPLK4 | |
| SCHEMBL10312122 | 0.79 | AURKA (0.42) | AURKANPC1RAB9AAURKBPLK4 | |
| SCHEMBL10312100 | 0.79 | AURKA (0.32) | AURKANPC1RAB9AAURKBSRC | |
| SCHEMBL10312107 | 0.78 | PAK4 (0.49) | AURKAAURKBPLK4GSK3BPAK4 | |
| SCHEMBL10312109 | 0.78 | PLK4 (0.50) | AURKAAURKBPLK4GSK3BPAK4 | |
| SCHEMBL10312087 | 0.77 | IGF1R (0.43) | SRCRETIGF1R | |
| SCHEMBL10312105 | 0.76 | HRH4 (0.50) | AURKAAURKBPLK4GSK3BPAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440055-B1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY LLC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | STK25, STK35, SGK2 | AURKA 793/4885NPC1 2224/4885RAB9A 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.